Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RCUS stock hub

Arcus Biosciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RCUSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.2B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

RCUS

In the news

Latest news · RCUS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-70

P25 -105.6P50 -46.5P75 -3.1

ROIC-39.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RCUS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

207

Groups with data

Currency

USD

Showing 207 of 207 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001724521
Company name	Arcus Biosciences, Inc.
Country	United States
Country code	US
Cusip	03969F109
Employees	601
Employees Change	-26%
Employees Change Percent	-4.15
Enterprise value	$2.4B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-03-15
Isin	US03969F1093
Last refreshed	2026-05-10
Market cap	$3.2B
Market cap category	Mid-Cap
Price	$25.36
Price currency	USD
Rev Per Employee	392,678.87x
Sector	Healthcare
Sic	2834
Symbol	RCUS
Website	https://arcusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.57%
EV Sales Forward	30.42x
EV/Sales	10.28x
FCF yield	-15.33%
P/B ratio	6.07x
P/S ratio	13.52x
PS Forward	39.99x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-168.64%
EBITDA Margin	-164.83%
Gross margin	-121.61%
Gross Profit	$-287M
Net Income	$-369M
Net Income Growth Years	0%
Pretax Margin	-156.36%
Profit Margin	-156.36%
Profit Per Employee	$-613,977
ROA	-23.11
Roa5y	-12.96
ROCE	-50.51
ROE	-69.95
Roe5y	-41.13
ROIC	-39.83

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	216.85%
Cagr3y	9.04%
Cagr5y	-3.59%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	67.38x
Revenue Growth Q	-39.29x
Revenue Growth Years	0x
Revenue Growth3 Y	25.64x
Revenue Growth5 Y	22.59x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.22
Assets	$997M
Cash	$822M
Current Assets	$844M
Current Liabilities	$209M
Debt	$113M
Debt Equity	$0.22
Equity	$524M
Interest Coverage	-39.8
Liabilities	$473M
Long Term Assets	$153M
Long Term Liabilities	$264M
Net Cash	$763M
Net Cash By Market Cap	$23.92
Net Cash Growth	-17.42%
Net Debt Equity	$-1.46
Tangible Book Value	$524M
Tangible Book Value Per Share	$4.18
WACC	8.99

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.04
Net Working Capital	$-174M
Quick ratio	3.97
Working Capital	$635M
Working Capital Turnover	$0.32

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-22.54%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	216.6%
200-day SMA	18.98
3Y total return	29.65%
50-day SMA	23.22
50-day SMA vs 200-day SMA	50over200
5Y total return	-16.72%
All Time High	49.1
All Time High Change	-48.35%
All Time High Date	2021-11-22
All Time Low	6.3
All Time Low Change	302.54%
All Time Low Date	2019-08-05
ATR	1.49
Beta	0.87
Beta1y	1.01
Beta2y	1.86
Ch YTD	6.42
High	25.7
High52	28.72
High52 Date	2026-04-22
High52ch	-11.7%
Low	24.33
Low52	7.72
Low52 Date	2025-05-08
Low52ch	228.71%
Ma50ch	9.2%
Premarket Change Percent	0.4
Premarket Price	$24.88
Premarket Volume	68,296
Price vs 200-day SMA	33.62%
RSI	55.72
RSI Monthly	62.46
RSI Weekly	65.45
Sharpe ratio	2.09x
Sortino ratio	3.46
Total Return	-22.54%
Tr YTD	6.42
Tr1m	14.91%
Tr1w	-1.25%
Tr3m	20.59%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	3
Analyst Price Target Top	$23
Analyst Ratings	Buy
Analyst Ratings Top	Hold
Earnings EPS Estimate	$-0.85
Earnings Revenue Estimate	26,387,648x
Earnings Revenue Estimate Growth	-5.76x
Operating Income	$-398M
Operating margin	-168.6
Price target	$32.5
Price Target Change	$28.16
Price Target Change Top	$-9.31

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	89,076,513%
Float Percent	70.82%
Net Borrowing	49,000,000
Shares Insiders	3.56%
Shares Institutions	73.44%
Shares Out	125,773,162
Shares Qo Q	5.82%
Shares Yo Y	22.54%
Short Float	12.43%
Short Ratio	10.28
Short Shares	8.8

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-552M
Average Volume	1,391,368.1x
Bv Per Share	4.18
CAPEX	$-1M
Ch1m	14.91
Ch1w	-1.25
Ch1y	216.6
Ch3m	20.59
Ch3y	29.65
Ch5y	-16.72
Ch6m	31.33
Change	2.34%
Change From Open	2.76
Close	24.78
Days Gap	-0.4
Depreciation Amortization	9,000,000
Dollar Volume	24,541,607.4
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$-398M
EBITDA	$-389M
EPS	$-3.23
F Score	2
FCF	$-489M
FCF EV Yield	-20.15x
FCF Per Share	$-3.89
Financing CF	349,000,000
Fiscal Year End	December
Founded	2,015
Investing CF	148,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-25
Ma150	21.66
Ma150ch	17.1%
Ma20	24.74
Ma20ch	2.51%
Net CF	9,000,000
Next Earnings Date	2026-08-05
Open	24.68
Optionable	Yes
Position In Range	75.18
Post Close	25.36
Postmarket Change Percent	-1.89
Postmarket Price	$24.88
Ppne	38,000,000
Pre Close	24.78
Price Date	2026-05-08
Ptbv Ratio	6.09
Relative Volume	0.7x
Revenue	236,000,000x
SBC By Revenue	26.69x
Share Based Comp	63,000,000
Tr6m	31.33%
Us State	California
Volume	967,729
Z Score	-0.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RCUS pay a dividend?

Capital-return profile for this ticker.

Performance

RCUS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RCUS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+73.4%

Float: +70.8% of shares outstanding

Insider ownership

+3.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RCUS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.7

Neutral momentum band

Price vs 200-day MA

+33.6%

50/200-day relationship not available

Beta (5Y)

0.87

Moves roughly with the market

Sharpe ratio

2.09

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RCUS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RCUS stock rating?

Arcus Biosciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RCUS analysis?

The full report lives at /stocks/RCUS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RCUS?

The latest report frames RCUS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RCUS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.